

Synthetic Studies toward the Mannopectimycins: Synthesis of Orthogonally Protected β -Hydroxyenduracididines


Kevin S. Olivier and Michael S. Van Nieuwenhze*

Department of Chemistry, Indiana University, 800 East Kirkwood Avenue,
Bloomington, Indiana 47405-7102

mvannieu@indiana.edu

Received January 27, 2010

ABSTRACT



The asymmetric synthesis of the nonproteinogenic amino acids (2S,3S,4'S)- β -hydroxyenduracididine 3 and (2R,3S,4'S)- β -hydroxyenduracididine 4 in orthogonally protected form in 15 total steps from Garner's aldehyde is reported. The former and *N*-glycosylated form of the latter are found in the glycopeptide antibiotic mannopectimycin.

The rapidly escalating fight against bacterial resistance to currently available therapies has created an urgent need for new antibiotic agents with novel modes of action. For example, *Staphylococcus aureus*, which has a long history of acquiring resistance to antibiotics, continues to pose problems for existing chemotherapeutic agents. In fact, methicillin-resistant *S. aureus* (MRSA) infections have been a significant health problem since the 1960s.¹ A recent study estimated that there were over 94000 cases of invasive MRSA infection in the United States in 2005.² While vancomycin has been an effective drug for treating these infections, recent identification of MRSA isolates possessing an intermediate level of resistance to vancomycin has

underscored the need for novel antibiotics that act via mechanisms that are orthogonal to currently used therapies.¹


The mannopectimycins are a group of cyclic glycopeptides originally isolated in the 1950s as an antibiotic complex produced by the LL-AC98 strain of *Streptomyces hygroscopicus*.³ They represent a novel class of lipoglycopeptide antibiotics that are assembled via a nonribosomal peptide synthetase (NRPS) pathway and have shown promising antibacterial activity against multidrug-resistant pathogens.⁴ Only in 2002 was a report of the complete structural and stereochemical assignment of the five members of this complex disclosed. The structures of the mannopectimycins and their biological activities are summarized in Table 1.


(1) Liñares, J. J. *Clin. Microbiol. Infect.* **2001**, 7, 8–15.

(2) Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K. *JAMA* **2007**, 298, 1763–1771.

(3) He, H.; Williamson, R. T.; Shen, B.; Graziani, E. I.; Yang, H. Y.; Sakya, S. M.; Petersen, P. J.; Carter, G. T. *J. Am. Chem. Soc.* **2002**, 124, 9729–9736.

(4) Magarvey, N. A.; Haltli, B.; Greenstein, M.; Hucul, J. A. *Antimicrob. Agents Chemother.* **2006**, 50, 2167–2177.

Table 1. Structures and Activities of the Mannopectimycins


mannopectimycin α - ϵ		MIC ($\mu\text{g/mL}$)	
		MRSA	<i>E. faecium</i>
1a; β	R = 	64-128	32-128
1b; α	R' =  R'' = H; R''' = H	>128	>128
1c; γ	R' = isovaleroyl; R'' = H; R''' = H	8	16-64
1d; δ	R' = isovaleroyl; R'' = isovaleroyl; R''' = H	8	8-64
1e; ϵ	R' = isovaleroyl; R'' = isovaleroyl; R''' = isovaleroyl	4	4-32


Mannopectimycins β – ϵ are active against a wide range of Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium*.^{5,6} A semisynthetic analogue of the mannopectimycins AC98–6446 has shown significantly greater potency than the natural mannopectimycins against MRSA, VRE, penicillin-resistant *Streptococcus pneumoniae*, and glycopeptide intermediate *S. aureus*.^{6–8} Mechanism of action studies have shown that mannopectimycin interferes with the late stages of bacterial cell wall synthesis, most likely the transglycosylation reaction, possibly through binding to lipid II.⁹

The peptide core of the mannopectimycins is composed of six amino acid residues of alternating D- and L-amino acids, three of which are nonproteinogenic. Two of these nonproteinogenic amino acids, the β -hydroxyenduracididines, have not been found in any other natural product although the biosynthetic pathway used for their construction is currently being studied.^{4,10} In addition, two of these non-

proteinogenic amino acids (D-tyrosine and β -D-hydroxyenduracididine) are glycosylated with mannose residues; the former is glycosylated with an α -(1,4)-linked-bis-mannopyranosyl pyranoside^{11,12} and the latter is N-glycosylated with an α -linked mannose residue.

An important element of any effort directed toward the total synthesis of mannopectimycin is development of an efficient asymmetric synthesis of the novel β -hydroxyenduracididine residues **3** and **4** with appropriate orthogonal protecting groups. Each of these residues is densely functionalized, every carbon atom in the amino acid backbone is heteroatom-substituted, and features three contiguous stereocenters. Synthetic routes to either of these unusual amino acids have yet to be reported. Our interest in studying the influence of structure on the biological activity of the mannopectimycins required an efficient and robust synthetic route to each of the β -hydroxyenduracididines. Herein, we detail our synthetic route to these mannopectimycin building blocks.

Given that the hydroxyenduracididines differ only in the stereochemical configuration at C-2, it was envisaged that they could be accessed from a common advanced intermediate. Our strategy, which is depicted in Scheme 1, involved

Scheme 1. Synthetic Strategy

the preparation of the α -nosylate ester **2**, which was subsequently manipulated to provide each of the hydroxyenduracididine diastereomers. Nosylate **2** could be accessed via Sharpless asymmetric dihydroxylation¹³ of an appropriately derivatized enoate precursor (e.g., **11**) followed by selective activation of the α -hydroxyl group via nosylation.¹⁴ The (2*S*,3*S*,4'*S*)-diastereomer **3** (L-absolute configuration) could be accessed via direct azide displacement of the nosylate group in **2**. Conversion of nosylate **2** to an epoxide intermediate followed by nucleophilic ring-opening

(5) He, H. *Appl. Microbiol. Biotechnol.* **2005**, *67*, 444–452.

(6) Weiss, W. J.; Murphy, T.; Lenoy, E. B.; Young, M. *Antimicrob. Agents Chemother.* **2004**, *48*, 1708–1712.

(7) Petersen, P. J.; Wang, T. Z.; Dushin, R. G.; Bradford, P. A. *Antimicrob. Agents Chemother.* **2004**, *48*, 739–746.

(8) Dushin, R. J.; Wang, T.-Z.; Sum, P.-E.; He, H.; Sutherland, A. G.; Ashcroft, J. S.; Graziani, E. I.; E., K. F.; Bradford, P. A.; Petersen, P. J.; Wheless, K. L.; How, D.; Torres, N.; Lenoy, E. B.; Weiss, W. J.; Lang, S. A.; Projan, S. J.; Shlaes, D. M.; Mansour, T. S. *J. Med. Chem.* **2004**, *47*, 3487–3490.

(9) Ruzin, A.; Singh, G.; Severin, A.; Yang, Y.; Dushin, R. G.; Sutherland, A. G.; Minnick, A.; Greenstein, M.; May, M. K.; Shlaes, D. M.; Bradford, P. A. *Antimicrob. Agents Chemother.* **2004**, *48*, 728–738.

(10) Haltli, B.; Tan, Y.; Magarvey, N. A.; Wagenaar, M.; Yin, X.; Greenstein, M.; Hucul, J. A.; Zabriskie, T. M. *Chem. Biol.* **2005**, *12*, 1163–1168.

(11) Babu, R. S.; Guppi, S. R.; O'Doherty, G. A. *Org. Lett.* **2006**, *8*, 1605–1608.

(12) Adinolfi, M.; Giacomini, D.; Iadonisi, A.; Quintavalla, A.; Valerio, S. *Eur. J. Org. Chem.* **2008**, 2895.


(13) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483–2547.

(14) (a) Fleming, P. R.; Sharpless, K. B. *J. Org. Chem.* **1991**, *56*, 2869–2875. (b) Denis, J.; Correa, A.; Greene, A. E. *J. Org. Chem.* **1990**, *55*, 1957–1959. (c) Watson, K. G.; Fung, Y. M.; Gredley, M.; Bird, G. J.; Jackson, W. R.; Gountzos, H.; Matthews, B. R. *J. Chem. Soc., Chem. Commun.* **1990**, 1018.

by azide would provide access to the (2*R*,3*S*,4'*S*)-diastereomer **4** (D-absolute configuration).^{14a}

The synthesis of nosylate **2** commenced with olefin **6**,¹⁵ which was prepared by Wittig olefination of (*S*)-Garner's aldehyde. As detailed in Scheme 2, acidic cleavage of the

Scheme 2. Synthesis of Common Intermediate **2**




N,O-acetonide and *N*-Boc protecting groups (6 N HCl, 1 h) was followed by guanidinylation with *N,N'*-bis-(benzyloxy-carbonyl)-*S*-methylisothiurea **7** (HgCl₂, Et₃N, DMF, 4 d) to afford alcohol **8** in 45% overall yield from **6**. Cyclization of **8** under Mitsunobu conditions (DIAD, Ph₃P, THF, -15 °C) provided alkene **9** that contained the 2-iminoimidazolidine group in partially protected form.

At this juncture, orthogonal protection of the remaining nitrogen atom of the 2-iminoimidazolidine was required in order to ensure that it could be selectively unmasked for subsequent glycosylation. Since the remainder of the synthetic route would leverage the Sharpless asymmetric dihydroxylation reaction and subsequent electrophilic activation/displacement reactions, the choice of protection for this nitrogen must satisfy several requirements. First, it must not contain electrophilic functionality capable of reacting with nearby hydroxyl groups that would be introduced with Sharpless asymmetric dihydroxylation. Second, it must not contain nucleophilic functionality that would be capable of displacing either of the activated hydroxyl groups. Third, it must be selectively cleaved under mild conditions that will not also cleave the neighboring Cbz-protecting groups. These restrictions rule out a number of commonly used protecting groups (e.g., carbamates, amides, benzyl, etc.).

Given these limitations, we chose to protect the remaining nitrogen atom of **9** with the (triisopropylsilyloxy)methyl (Tom) group.¹⁶ Thus, olefin **9** was treated with Tom-Cl (KHMDS, toluene, 1 h) to provide the Tom-protected olefin **10** in modest yield. Olefin **10** was subjected to a dihydroxylation/oxidative cleavage sequence (OsO₄, NMO, THF/H₂O/*t*-BuOH then NaIO₄, CH₂Cl₂/H₂O) and the crude aldehyde was treated with methyl (triphenylphosphoranylidene)acetate at low concentration in THF to give enoate **11** in 71% overall yield and a 17:1 product ratio favoring the desired (*E*)-isomer. Sharpless asymmetric dihydroxylation (AD-mix α, *t*-BuOH/H₂O) proceeded cleanly to provide a single diol diastereomer **12**. Monosulfonylation of diol **12** (Nos-Cl, Et₃N, CH₂Cl₂, -40 to 0 °C) proceeded smoothly to provide nosylate **2** in 71% yield.^{14a}

The nosylate intermediate **2** was then transformed into orthogonally protected (2*S*,3*S*,4'*S*)-diastereomer **3** (β-*L*-hydroxyenduracididine) in two steps (Scheme 3).

Scheme 3. Synthesis of the Diastereomeric β-Hydroxyenduracididines from Common Intermediate **2**



Nucleophilic displacement of the nosylate in **2** with sodium azide (NaN₃, DMF, 50 °C, 78%) provided an intermediate azido alcohol which was subjected to a one-pot Staudinger reduction (PPh₃, THF/H₂O, 4 h) and Boc protection (Boc₂O, NaHCO₃, 12 h) to provide building block **3** in 62% overall yield from the intermediate azido alcohol.

Whereas **3** was prepared via inversion of the stereochemical configuration at C-2, its epimer **4** was obtained by double inversion at that center, as outlined in Scheme 3. Conversion of **2** to epoxide **13** (KHMDS, THF/tol, -78 °C, 59%) followed by nucleophilic ring opening in the presence of sodium azide and pyridinium *p*-toluenesulfonate (DMF, 44%) afforded an intermediate azido alcohol which was converted to the orthogonally protected (2*R*,3*S*,4'*S*)-diastereomer **4** (β-*D*-hydroxyenduracididine) via the aforementioned Staudinger reduction/Boc-protection procedure.

In conclusion, we have completed the first chemical synthesis of the (2*S*,3*S*,4'*S*)- and (2*R*,3*S*,4'*S*)-hydroxyendura-

(15) Campbell, A. D.; Raynham, T. M.; Taylor, R. J. K. *Synthesis* **1998**, 1707–1709.

(16) Pitsch, S.; Weiss, P. A.; Stutz, J. A.; Wu, X. *Helv. Chim. Acta* **2001**, 84, 3773–3795.

cididines in orthogonally protected form. Access to each of these nonproteinogenic amino acids will assist efforts directed at total synthesis of members of the mannopeptimycin class of lipoglycopeptide antibiotics and aid semisynthetic efforts directed toward identification of mannopeptimycin derivatives with improved biological activity profiles. Furthermore, these novel amino acids will support efforts directed toward elucidating the mode of action and binding site(s) utilized by the mannopeptimycins. Our results from these studies will be presented in due course.

Acknowledgment. Financial support provided by the National Institutes of Health (AI 059327) and Indiana University is gratefully acknowledged.

Supporting Information Available: Experimental procedures and tabulated spectroscopic data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL100219A